Navigation Links
ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
Date:1/7/2011

lments.

The target company has no employees, but in connection with a transaction ADVENTRX expects to retain the services of certain members of the target company's management team who have been involved in the development of the TPC.

About the Planned Development of the Target Company's Lead Product Candidate

If a transaction is consummated, ADVENTRX expects to conduct a phase 3 clinical trial of the TPC for the treatment of sickle cell crisis. Prior to initiating this study, ADVENTRX would discuss the design and analytical methodologies of the study with the FDA. Based on its evaluation to-date, ADVENTRX believes the out-of-pocket cost to submit an NDA covering the TPC would be approximately $15 million to $25 million over 3 years. ADVENTRX expects to agree to commit approximately $1.5 million to conduct particular activities during the first 12 months following consummation of the acquisition. The principal source of market exclusivity for the TPC for the sickle cell disease indication is expected to be based on orphan drug exclusivity. The FDA has granted an orphan drug designation for the TPC for the treatment of sickle cell crisis.  

The foregoing is based on ADVENTRX's current discussions with the target company. There is no guarantee that definitive agreements will be entered into or that ADVENTRX will consummate a transaction with the target company or that any transaction ADVENTRX ultimately may consummate will be on the terms described above.

About the Target Company's Lead Product Candidate

The TPC is a purified form of a nonionic block copolymer surfactant that is believed to adhere to hydrophobic surfaces that develop when cells are damaged. The TPC is designed to restore hydration lattices and minimize the cascade of adhesive, inflammatory and coagulation responses that cause adhesion of cells, impaired blood flow and tissue ischemia. Improving blood flow in the microvasculatu
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SOUTH PLAINFIELD, N.J., July 30, 2015 PTC ... corporate update and reported financial results for the second ... is progressing on many fronts across the organization.  We ... largest Duchenne muscular dystrophy clinical trial ever conducted with ... W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania ... injury caused by diabetes after many years of suffering and using medications with strong ... didn’t want to ask for extra time off or wait longer hours in the ...
(Date:8/3/2015)... ... ... Did you know that there are thousands of Seniors or Elderly ... options which A-1 Home Care Agency specialize in? In fact, diversity, multi-cultural, financing options, ... Care Agency is known for. , With all the Los Angeles ...
(Date:8/2/2015)... Michigan (PRWEB) , ... August ... ... (POP) results when the supportive muscles and connective tissues of a woman’s ... this weakness and damage include straining, heavy lifting, obesity, constipation, multiple vaginal ...
(Date:8/1/2015)... ... August 01, 2015 , ... Have you ever wondered what “Karma” really means? Does it ... word “Karma.” , Vedic tradition, which gave birth to Hinduism, is one of the ... central concepts of this tradition. According to the wisdom of this heritage, Karma is a ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
Breaking Medicine News(10 mins):Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... chromosome containing a specific gene associated with susceptibility to ... in the Journal of Infectious Diseases and ... genes may affect the severity of symptoms and frequency ... have implications for the development of new drugs to ...
... detecting very small tumors. However, it fails to find ... benign and malignant disease. New research published in BioMed ... new and potentially more sensitive method using tumortargeted magnetic ... A team of researchers from University of New Mexico ...
... Reporter , THURSDAY, Oct. 27 (HealthDay News) -- More children ... many of these children are graduating from high school and ... Unfortunately, this critical crossroads is precisely the time that supportive ... "What we,re seeing now is this group of adults with ...
... Amanda Gardner HealthDay Reporter , THURSDAY, Oct. 27 ... only rudimentary speech therapy after suffering a massive stroke at ... and spent a year-and-a-half completely isolated, unable to communicate, socialize ... Speech Labs in Texas, one of a handful of organizations ...
... COLUMBUS, Ohio A new fourth-generation oncolytic virus designed ... has shown greater effectiveness than earlier versions when tested ... Researchers at the Ohio State University Comprehensive Cancer Center ... Solove Research Institute (OSUCCC James) are developing the ...
... -- Trying to bolster your self-esteem by giving yourself ... feel depressed, according to a new study. Researchers ... high school students in Hong Kong. High and ... but participants who rated their performance as much better ...
Cached Medicine News:Health News:Study finds specific gene linked to cold sore susceptibility 2Health News:Job Market Tough for Young Adults With Autism 2Health News:Job Market Tough for Young Adults With Autism 3Health News:Speech Therapy Key to Stroke Rehab, But Many Miss Out 2Health News:Speech Therapy Key to Stroke Rehab, But Many Miss Out 3Health News:New oncolytic virus shows improved effectiveness in preclinical testing 2Health News:Honest Self-Assessment Better Than False Praise 2
The High Speed Drill handpiece is a well-balanced, high performance drill that provides high speed for,bone sculpting, along with power for difficult osteotomies. Must be used with the 6401-000 foot ...
... with hand throttle. Accepts all 1000 and ... air hose 9000-000, or existing hose with ... 9013-000, or existing hose with Linvatec/Hall connector ... existing hose with 3M connector (1000-300). , ...
Pneumatic micro sagittal saw, 30k cpm, available with various hose connector styles....
... Introducing the new large power ... function as both cordless AND electric ... Its the versatility the industry has ... the MicroAire name. Power ...
Medicine Products: